TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use
Total Page：16
File Type：pdf, Size：1020Kb
TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS From Basic Science to Clinical Use Edited by ARPAD SZALLASI MD, PHD Department of Pathology, Monmouth Medical Center, Long Branch, NJ, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London, EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First published 2015 Copyright © 2015 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN: 978-0-12-420024-1 For information on all Academic Press publications visit our website at store.elsevier.com Printed and bound in the United States Contributors M. Allen McAlexander Neuronal Targets Team, Ana Charrua IBMC—Instituto de Biologia Respiratory Therapy Area, GlaxoSmithKline Phar- Molecular e Celular da Universidade do maceuticals, King of Prussia, Pennsylvania, USA Porto; Departamento de Urologia, Faculdade Ganesan Baranidharan Consultant in Pain de Medicina da Universidade do Porto and Medicine, Leeds Teaching Hospitals NHS trust: Departamento de Doenças Renais, Urológicas D ward, Seacroft Hospital, Leeds, LS14 6UH e Infecciosas, Faculdade de Medicina da Uni- versidade do Porto, Porto, Portugal Ralf Baron Division of Neurological Pain Research and Therapy, Department of Neurol- Francisco Cruz IBMC—Instituto de Biologia ogy, University Hospital Schleswig-Holstein, Molecular e Celular da Universidade do Kiel, Germany Porto; Departamento de Urologia, Faculdade de Medicina da Universidade do Porto; De- Arun K. Bhaskar Consultant in Pain Medicine, partamento de Doenças Renais, Urológicas e Leeds Teaching Hospitals NHS trust: D ward, Infecciosas, Faculdade de Medicina da Uni- Seacroft Hospital, Leeds, LS14 6UH versidade do Porto and Departamento de Mahendra Bishnoi Department of Nutritional Urologia, Hospital São João, Porto, Portugal Sciences, and Technology, National Agri-Food Matthew A.J. Duncton Renovis, Inc. (a wholly Biotechnology Institute (NABI), SAS Nagar, owned subsidiary of Evotec AG), South San India Francisco, California, USA Jill-Desiree Brederson Global Medical Commu- Madeleine Ennis Centre for Infection and Im- nications, Research and Development, AbbVie munity, School of Medicine, Dentistry and Inc., North Chicago, Illinois, USA Biomedical Sciences, Queen's University Bel- Dorothy Cimino Brown Veterinary Clinical In- fast, Belfast, Northern Ireland, UK vestigations Center and Department of Clinical Susan Fleetwood-Walker Centre for Integra- Studies, School of Veterinary Medicine, tive Physiology, School of Biomedical Sciences, University of Pennsylvania, Philadelphia, College of Medicine & Veterinary Medicine, Pennsylvania, USA University of Edinburgh, Scotland, UK Nigel W. Bunnett Monash Institute of Phar- maceutical Sciences, and Department of Ehud Goldin SENS Research Foundation, Pharmacology, The University of Melbourne, Mountain View, CA, USA Parkville, Victoria, Australia Arthur Gomtsyan Department of Chemistry, Ingolf Cascorbi Institute of Experimental and Research and Development, AbbVie Inc., North Clinical Pharmacology, University Hospital Chicago, Illinois, USA Schleswig-Holstein, Kiel, Germany Huizhen Huang Department of Neurobiology, Michael J. Caterina Department of Neurosur- University of Pittsburgh; Pittsburgh Center for gery; Department of Biological Chemistry; Pain Research, Pittsburgh, PA, USA, and Tsing- Solomon H. Snyder Department of hua University School of Medicine, Beijing, China Neuroscience and Neurosurgery Pain Re- Gerald Hunsberger Neuronal Targets Team, Re- search Institute, Johns Hopkins School of spiratory Therapy Area, GlaxoSmithKline Phar- Medicine, Baltimore, Maryland, USA maceuticals, King of Prussia, Pennsylvania, USA ix x CONTRIBUTORS Michael J. Iadarola Anesthesia Section, Depart- Magdalene Moran Hydra Biosciences ment of Perioperative Medicine, Clinical Cen- Cambridge, MA, USA ter, NIH, Bethesda, Maryland, USA Christopher Neipp Flexible Discovery Unit, Neelima Khairatkar Joshi Glenmark Research GlaxoSmithKline Pharmaceuticals, King of Centre, Navi Mumbai, Glenmark Pharmaceuti- Prussia, Pennsylvania, USA cals Ltd, India Bernd Nilius Katholieke Universiteit of Leu- Pragyanshu Khare Department of Nutritional ven, Department of Cellular and Molecular Sciences and Technology, National Agri-Food Medicine, Laboratory of Ion Channel Research Biotechnology Institute (NABI), SAS Nagar, and TRP Research Platform Leuven (TRPLe), India Campus Gasthuisberg, Leuven, Belgium Kirill Kiselyov Department of Biological Sci- James C. Parker Department of Physiology and ences, University of Pittsburgh, Pittsburgh, Center for Lung Biology, University of South PA, USA Alabama, Mobile, Alabama, USA Ari Koivisto Research and Development, Ori- Antti Pertovaara Institute of Biomedicine/ onPharma, Orion Corporation, Turku, Finland Physiology, University of Helsinki, Helsinki, Kanthi K. Kondepudi Department of Food Sci- Finland ences and Technology, National Agri-Food Bio- Koenraad Philippaert Katholieke Universiteit technology Institute (NABI), SAS Nagar, India of Leuven, Department of Cellular and Molec- Artem Kondratskyi Inserm U-1003, Equipe la- ular Medicine, Laboratory of Ion Channel Re- bellisée par la Ligue Nationale contre le cancer, search and TRPLe (TRP Research Platform Laboratory of Excellence Ion Channels Science Leuven), Campus Gasthuisberg, Leuven, and Therapeutics, Université Lille 1, Villeneuve Belgium d’Ascq, France Daniel P. Poole Monash Institute of Pharma- Ina Kraus-Stojanowic Institute of Experimental ceutical Sciences; Department of Anatomy & and Clinical Pharmacology, University Hospi- Cell Biology, The University of Melbourne, tal Schleswig-Holstein, Kiel, Germany Parkville, Victoria, Australia TinaMarie Lieu Monash Institute of Pharma- Louis S. Premkumar Department of Pharma- ceutical Sciences, Parkville, Victoria, Australia cology, Southern Illinois University-School of Medicine, Springfield, Illinois, USA Daoyan Liu Department of Hypertension and Endocrinology, Center for Hypertension and Natalia Prevarskaya Inserm U-1003, Equipe la- Metabolic Diseases, Daping Hospital, Third bellisée par la Ligue Nationale contre le cancer, Military Medical University, Chongqing Insti- Laboratory of Excellence Ion Channels Science tute of Hypertension, Chongqing, China and Therapeutics, Université Lille 1, Villeneuve d’Ascq, France Nancy Luo Division of Cardiology, Department of Medicine, Duke University School of Medi- Pradeep Rajasekhar Monash Institute of Phar- cine, Durham, North Carolina, USA maceutical Sciences, Parkville, Victoria, Australia Lorcan McGarvey Centre for Infection and Im- munity, School of Medicine, Dentistry and Bio- Paul Rosenberg Division of Cardiology, De- medical Sciences, Queen's University Belfast, partment of Medicine, Duke University School Belfast, Northern Ireland, UK of Medicine, Durham, North Carolina, USA Rory Mitchell Centre for Integrative Physiol- Sarah E. Ross Department of Neurobiology; De- ogy, School of Biomedical Sciences, College of partment of Anesthesiology; Pittsburgh Center Medicine & Veterinary Medicine, University of for Pain Research, and Center for Neuroscience Edinburgh, Scotland, UK Research at the University of Pittsburgh, Pitts- burgh PA, USA CONTRIBUTORS xi Kavisha Singh Division of Cardiology, Depart- Mary I. Townsley Department of Physiology ment of Medicine, Duke University School of and Center for Lung Biology, University of Medicine, Durham, North Carolina, USA South Alabama, Mobile, Alabama, USA Lindsey M. Snyder Department of Neurobiol-